Oligonucleotide-based therapeutics: A new frontier of drug development with capillary-electrophoresis-mass spectrometry

4 August 2022

Here, we speak with Vladimir Papov, research and development scientist for Boehringer Ingelheim, as he discusses the importance of mass spectrometry and the benefits of his collaboration with 908 Devices on his work in oligonucleotide analysis. The 908 Devices ZipChip platform has allowed Papov to obtain very high-resolution MS-MS data which provides him with the information to verify that the sequence of oligonucleotide is correct. This is critical in drug development to ensure the correct action of oligonucleotide-based therapeutics.